New hope for advanced blood cancer patients in trial
NCT ID NCT05074355
Summary
This study is testing whether a combination of two drugs, venetoclax and azacitidine, is safe and effective for people with advanced forms of a rare blood cancer called myeloproliferative neoplasm. The trial will enroll about 40 participants to see if the treatment can put the disease into remission. The goal is to control the aggressive disease and potentially allow eligible patients to proceed to a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.